血液吸附:第30届急性疾病质量倡议工作组共识报告
该共识报告由急性疾病质量倡议工作组制定,针对基于吸附的体外治疗在中毒、药物过量、炎症状态、脓毒症及急慢性肝肾衰竭等疾病中的应用进行总结。现有数据显示血液吸附具有临床可接受的短期生物相容性和安全性,技术可行且能实验性清除特定靶分子,但现代血液吸附仍属新型实验性干预,数据有限,需大量研究。
要点
- 血液吸附短期生物相容性和安全性可接受,技术可行。
- 内源性和外源性中毒中已证实可清除靶分子。
- 内毒素吸附大型研究识别出可能的目标表型供随机对照试验。
核心结论
- 现代血液吸附仍属新型实验性干预,数据有限,需大量研究议程。
研究设计与样本
- 急性疾病质量倡议共识会议,基于现有体外、实验和临床观察证据。
主要发现
- 血液吸附具有临床可接受的短期生物相容性、安全性和技术可行性。
- 实验证明可清除特定靶分子,内源性和外源性中毒中体内清除已获证实。
- 先导研究显示对生理学有潜在有益效应,内毒素吸附大型研究识别出可能的目标表型。
- 部分研究提出伤害担忧或未能显示获益。
局限性
- 现代血液吸附数据有限,仍为实验性干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adsorption-based extracorporeal therapies have been subject to technical developments and clinical application for close to five decades. More recently, new technological developments in membrane and sorbent manipulation have made it possible to deliver more biocompatible extracorporeal adsorption therapies to patients with a variety of conditions. There are several key rationales based on physicochemical principles and clinical considerations that justify the application and investigation of such therapies as evidenced by multiple ex vivo, experimental and clinical observations. Accordingly, unspecific adsorptive extracorporeal therapies have now been applied to the treatment of a wide array of conditions from poisoning to drug overdoses, to inflammatory states and sepsis, and acute or chronic liver and kidney failure. In response to the rapidly expanding knowledge base and increased clinical evidence, we convened an Acute Disease Quality Initiative consensus conference dedicated to such treatment. The data show that hemoadsorption has clinically acceptable short-term biocompatibility and safety, technical feasibility and experimental demonstration of specified target molecule removal. Pilot studies demonstrate potentially beneficial effects on physiology and larger studies of endotoxin-based hemoadsorption have identified possible target phenotypes for larger randomized controlled trials. Moreover, in a variety of endogenous and exogenous intoxications, removal of target molecules has been confirmed in vivo. However, some studies have raised concerns about harm, or failed to deliver benefits. Thus, despite many achievements, modern hemoadsorption remains a novel and experimental intervention with limited data, and a large research agenda.
引用
- Bellomo R, Ankawi G, Bagshaw SM, et al. Hemoadsorption: consensus report of the 30th Acute Disease Quality Initiative workgroup. Nephrol Dial Transplant. 2024. PMID: 38621759. doi:10.1093/ndt/gfae089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。